Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812110 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL24866254 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL6247529 | 0.83 | CAD (0.43) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL22207692 | 0.83 | KDM4E (0.39) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064309 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064029 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064041 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13611400 | 0.81 | KDM4E (0.41) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL5808266 | 0.80 | TGFBR1 (0.44) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL4659641 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425907-B | Medical gel and application thereof in preparation of magnesium sulfate wet application | 中国人民解放军总医院第七医学中心 | 2024-03-01 | — | — | CN | disclosed |
| CN-116425907-A | Medical gel and application thereof in preparation of magnesium sulfate wet application | 中国人民解放军总医院第七医学中心 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023280280-A1 | FUSED-RING COMPOUND THAT ACTS AS KRAS G12D INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-01-12 | — | — | WO | disclosed |
| CN-110642736-A | Synthesis method of acetamido-3-methyl chloropropionate | 湖北宇阳药业有限公司 | 2020-01-03 | — | — | CN | disclosed |
| CN-104003894-A | Method for preparing N-acetyl-beta-chlorine-L-alanine methyl ester | ZHEJIANG JIAHUA CHEMICAL CO LTD | 2014-08-27 | — | — | CN | disclosed |
| CN-104003894-A | Method for preparing N-acetyl-beta-chlorine-L-alanine methyl ester | ZHEJIANG JIAHUA CHEMICAL CO LTD | 2014-08-27 | — | — | CN | disclosed |
| WO-2009098251-A1 | NOVEL CYCLOALKANONE β-SUBSTITUTED ALANINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2009-08-13 | — | — | WO | disclosed |
| EP-1615885-A1 | B -FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050143427-A1 | [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions | BARVIAN NICOLE C (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2004092132-A1 | [B]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-5101039-A | Carboxyindoles, hypotensive agents, inhibitors of angiotensin converting enzyme | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-31 | — | — | US | disclosed |
| US-5008400-A | Chemical intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-04-16 | — | — | US | disclosed |
| US-4933361-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-12 | — | — | US | disclosed |
| EP-0084164-B1 | DERIVATIVES OF BICYCLIC AMINO ACIDS, PROCESS FOR THEIR PREPARATION, AGENTS CONTAINING THEM AND THEIR USE, AS WELL AS BICYCLIC AMINO ACIDS AS INTERMEDIATES, AND PROCESS FOR PREPARING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-28 | — | — | EP | disclosed |
| EP-0170775-A1 | Derivatives of bicyclic amino acids, processes for their preparation, agents containing them and their use as well as bicyclic amino acids as intermediates and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-02-12 | — | — | EP | disclosed |
| EP-0084164-A2 | Derivatives of bicyclic amino acids, process for their preparation, agents containing them and their use, as well as bicyclic amino acids as intermediates, and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143427-A1 | [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions | PRAP1, PRR12, PPIB | SMN1; SMN2 4134/4885KDM4E 3350/4885MAPT 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.